Cargando…

Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer

Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for about 20% of all breast cancers and this subtype has been historically associated with worse prognosis. Margetuximab is a chimeric and Fc-engineered monoclonal antibody directed to HER2 that can enhance the activatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schlam, Ilana, Nunes, Raquel, Lynce, Filipa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059982/ https://www.ncbi.nlm.nih.gov/pubmed/35509453 http://dx.doi.org/10.2147/OTT.S272197

Ejemplares similares

A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer
por: Alasmari, Moudi M.
Publicado: (2022)

Significant response to margetuximab in Chinese HER2-positive metastatic breast cancer patient who progressed after second-line targeted therapy
por: Li, Jiaping, et al.
Publicado: (2023)

Margetuximab: An active alternative for later‐line therapy in patients with HER2‐positive advanced breast cancer
por: Zhou, Yunxiang, et al.
Publicado: (2023)

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
por: Schlam, Ilana, et al.
Publicado: (2021)

Complete response in patient with liver metastasis of HER2-positive breast cancer following therapy with margetuximab: a case report
por: Chang, Haiyan, et al.
Publicado: (2023)

The tumor immune microenvironment of primary and metastatic HER2− positive breast cancers utilizing gene expression and spatial proteomic profiling
por: Schlam, Ilana, et al.
Publicado: (2021)

Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A
por: Catenacci, D.V.T., et al.
Publicado: (2022)

Overcoming Resistance to HER2-Directed Therapies in Breast Cancer
por: Schlam, Ilana, et al.
Publicado: (2022)

How I treat HER2-low advanced breast cancer
por: Schlam, Ilana, et al.
Publicado: (2023)

Economic evaluation of margetuximab vs. trastuzumab for pretreated ERBB2-positive advanced breast cancer in the US and China
por: Tang, Zhiyuan, et al.
Publicado: (2022)

Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer
por: Garrido-Castro, Ana C., et al.
Publicado: (2023)

Bone-Modifying Agents in Early-Stage and Advanced Breast Cancer
por: Heeke, Arielle, et al.
Publicado: (2018)

Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial
por: Rugo, Hope S., et al.
Publicado: (2023)

Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer
por: Pernas, Sonia, et al.
Publicado: (2022)

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial
por: Rugo, Hope S., et al.
Publicado: (2021)

Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date
por: Varella, Leticia, et al.
Publicado: (2023)

Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer
por: Mittal, Abhenil, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases
por: Schlam, Ilana, et al.
Publicado: (2022)

Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date
por: Chong, Julio T, et al.
Publicado: (2018)

Safety and Efficacy of Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Advanced Breast Cancer: A Head-to-Head Comparison of Margetuximab versus Trastuzumab
por: Zhang, Liyi
Publicado: (2021)

Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
por: Linehan, Anna S, et al.
Publicado: (2021)

Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases?
por: Schlam, Ilana, et al.
Publicado: (2021)

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study
por: Lynce, F., et al.
Publicado: (2019)

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies
por: Morganti, Stefania, et al.
Publicado: (2023)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date
por: Criscitiello, Carmen, et al.
Publicado: (2018)

Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer
por: Montagna, Emilia, et al.
Publicado: (2019)

Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer
por: Hackshaw, Michelle D., et al.
Publicado: (2020)

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
por: Sadeghi, Saeed, et al.
Publicado: (2014)

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
por: Pizzuti, Laura, et al.
Publicado: (2021)

HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments
por: Essadi, Ismail, et al.
Publicado: (2023)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date [Corrigendum]
Publicado: (2018)

Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis
por: Honkanen, Tiia J., et al.
Publicado: (2021)

Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
por: Facchinetti, Francesco, et al.
Publicado: (2019)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer
por: Lynce, Filipa, et al.
Publicado: (2018)

The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review
por: Mendes, Diogo, et al.
Publicado: (2015)

Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
por: Callahan, Rena
Publicado: (2014)

ASCO 2018: highlights in HER2-positive metastatic breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2018)

Trastuzumab beyond progression in HER2‐positive metastatic breast cancer
por: Al‐Naqqash, Manwar, et al.
Publicado: (2021)

Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer
por: Beasley, Marcie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j1cdrfom5eu5bj7pek31rl6ota